Calidi Biotherapeutics offers a novel allogeneic stem cell delivery platform to target oncolytic viruses. Image courtesy of Calidi.

Specifically, the patents cover therapies using an oncolytic adenovirus in combination with a clinical-grade allogeneic neural stem cell line, according to Calidi. Scientists at City of Hope and the University of Chicago have used City of Hope's human neural stem cell line to selectively deliver an oncolytic adenovirus to tumor sites, Calidi said. They have received U.S. Food and Drug Administration approval to begin a phase I trial in recurrent glioma patients.

Patient trials are expected to begin in the first quarter of 2022. The license agreement transfers the investigational new drug application to Calidi for commercial development of a licensed product, according to the company. Calidi said it will have commercial exclusivity in using neural stem cells with the CRAd-pk-S-7 adenovirus for oncolytic virotherapy.

Financial details of the agreement were not disclosed.

Imugene licenses CD19-expressing oncolytic virus from City of Hope
Immuno-oncology company Imugene has licensed patents from the City of Hope that pave the way for an immunotherapy for solid tumors that combines a CD19-expressing...

CytoImmune, City of Hope ink CAR-NK cell therapy agreements
CytoImmune Therapeutics and City of Hope plan to collaborate on a portfolio of chimeric antigen receptor (CAR)-natural killer (NK) cell therapies through...

AB Science, University of Chicago to research COVID-19 treatments
AB Science has inked an exclusive licensing deal with the University of Chicago to conduct research for the prevention and treatment of COVID-19 and other...

City of Hope initiates SARS-CoV-2 vaccine phase I trial
The City of Hope has begun a phase I clinical trial of COH04S1, which is its investigational SARS-CoV-2 vaccine, in healthy volunteers between the ages...